HB 2302
In CommitteeHouse
Pharmacist prescriptive auth
Expanding prescriptive authority for pharmacists.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill expands pharmacists’ authority in Washington to diagnose and prescribe medications independently—without needing a physician-led collaborative agreement—based on their extensive education and clinical training. It removes administrative barriers to full-scope practice while affirming pharmacists’ safety record and role in improving access, especially in underserved areas.
- Authorizes pharmacists to diagnose and prescribe medications independently—without requiring a collaborative drug therapy agreement with a physician—based on their education, training, and experience.
- Removes the requirement to maintain, file, or obtain approval for collaborative drug therapy agreements, eliminating an administrative burden the legislature found does not improve patient safety or outcomes.
- Confirms that pharmacists have long practiced under collaborative agreements since 1979 and that the state has no record of patient harm from such practice, supporting full-scope authorization.
- Amends definitions in Chapter 18.64 RCW to clarify terms like 'practice of pharmacy' and 'prescribe' to reflect pharmacists’ expanded authority.
- Updates RCW 69.41.030 to explicitly include pharmacists as authorized prescribers—removing the previous limitation tied to collaborative agreements—while maintaining all existing exceptions for other licensed providers.
Who is affected
- Pharmacists — Pharmacists gain the legal authority to diagnose and prescribe medications independently, without requiring a collaborative agreement with a physician, expanding their scope of practice to match their education and training.
- Patients in rural and underserved communities — Patients—especially in rural, underserved, or medically underserved areas—gain improved access to care, including chronic disease management and behavioral health services, through more readily available pharmacist-led care.
- Health care systems and clinics — Health systems and clinics may see reduced administrative burden and improved care coordination, as pharmacists can manage medication therapy directly without relying on physician-led protocols.
- Pharmacy regulatory agencies — The Pharmacy Quality Assurance Commission (PQAC) will no longer need to approve or maintain records of collaborative drug therapy agreements, shifting oversight responsibility to professional standards and continuing education.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Patients—especially in rural, underserved, and medically underserved communities—will gain significantly improved access to medication management for chronic conditions (e.g., diabetes, hypertension, behavioral health) without needing to schedule separate appointments with physicians, reducing travel, wait times, and out-of-pocket costs.
HealthcarePeopleRef: Sec. 1(2) (pharmacists’ 1,740+ hours of direct patient care training); Sec. 1(4) (eliminating administrative burden of collaborative agreements); Sec. 2(32) (expanding 'practice of pharmacy' to include independent diagnosis and prescribing)The bill is supported by 45+ years of documented safe practice under collaborative agreements and a 2020 AG opinion affirming pharmacists’ diagnostic authority—indicating low baseline risk. Removing administrative barriers (e.g., filing agreements) does not weaken safety oversight, as pharmacists remain subject to licensing standards, continuing education, and disciplinary action by PQAC.
Public SafetyPeopleRef: Sec. 1(3) (no record of patient harm under existing collaborative agreements); Sec. 2(32) (explicit inclusion of diagnosis and prescribing in scope of practice); Sec. 3 & 4 (removing 'approved by a practitioner' limitation in RCW 69.41.030)By allowing pharmacists to manage medication therapy independently—particularly for mental health and addiction—this bill can reduce delays in treatment initiation, improve adherence, and support integrated care models, especially where psychiatrists and behavioral health providers are severely scarce.
HealthcarePeopleRef: Sec. 1(4) (intent to 'improve outcomes in both behavioral and physical health'); Sec. 2(32) (expanding scope to include diagnosis and prescribing based on education, training, and experience)Pharmacies and health systems may reduce administrative overhead and improve staffing efficiency by allowing pharmacists to manage medication therapy without waiting for physician sign-offs—potentially lowering operational costs and enabling pharmacists to practice at the top of their license, increasing job satisfaction and retention.
Business & EmploymentPeopleRef: Sec. 1(4) (eliminating administrative burden of collaborative agreements); Sec. 2(32) (removing requirement for 'protocols approved by a practitioner')This bill directly addresses Washington’s primary care shortage by leveraging the high accessibility of community pharmacists (open evenings/weekends, no appointment needed), enabling them to provide preventive care, chronic disease management, and basic diagnostics—effectively turning pharmacies into de facto outpatient clinics in underserved areas.
HealthcarePeopleRef: Sec. 1(1) (legislature’s concern about provider shortages in rural/underserved areas); Sec. 1(2) (pharmacists’ extensive clinical training); Sec. 2(32) (expansion of scope to include independent diagnosis and prescribing)
Potential Concerns (3)
Removal of physician oversight may increase risk of misdiagnosis or inappropriate prescribing—especially for complex or ambiguous conditions—since pharmacists, while highly trained in pharmacotherapy, are not trained in full-spectrum differential diagnosis or physical assessment. The bill affirms pharmacists have prescribed under collaborative agreements since 1979 with no recorded harm, but that historical record reflects *supervised* practice; independent practice introduces a new risk profile not yet empirically evaluated.
Public SafetyPeopleRef: Sec. 2(32) (new definition of 'Practice of pharmacy' including 'diagnosing and the prescribing or ordering of drugs and devices based on his or her education, training, and experience')The bill does not require pharmacists to maintain liability insurance or establish clear referral pathways for conditions outside their scope, potentially leaving patients without recourse if adverse events occur—and could fragment care coordination if pharmacists operate outside traditional care teams.
HealthcareLean peopleRef: Sec. 2(32) (expansion of 'Practice of pharmacy' to include independent diagnosis and prescribing)Without mandatory collaborative protocols, there is no statutory requirement for pharmacists to consult with or refer to physicians for conditions outside their scope (e.g., suspected cancer, acute neurological events), potentially delaying critical specialist care—especially in rural areas where specialists are already scarce.
HealthcareLean peopleRef: Sec. 2(32) and Sec. 3 & 4 (removal of collaborative agreement requirement and statutory reference to 'protocols approved by a practitioner')
Who Is Most Affected
Pharmacists gain full prescriptive and diagnostic authority, increasing autonomy, job satisfaction, and potential earnings—especially those in community or retail settings who can now offer direct patient services without physician oversight.
Patients in rural, low-income, or medically underserved areas benefit most: they gain easier access to chronic disease management, mental health support, and preventive care without long travel or wait times—reducing disparities in health outcomes.
Large pharmacy chains (e.g., CVS, Walgreens) and health systems may see operational efficiencies and cost savings from streamlined workflows, but small independent pharmacies may face mixed outcomes—some benefit from expanded services, while others may lack resources to train staff for full clinical roles.
The Pharmacy Quality Assurance Commission (PQAC) will shift from approving individual agreements to oversight via professional standards and continuing education—reducing administrative burden but requiring new regulatory capacity to monitor independent practice quality.
Physicians—especially primary care and rural practitioners—may experience reduced administrative burden from signing off on collaborative agreements, but could face increased referrals for conditions pharmacists identify as beyond their scope, potentially straining already tight specialist capacity.